Back to results
US 9,868,787 B2Granted
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
AssigneeThe University of North Carolina at Chapel Hill
InventorsDavid R. Clemmons, Laura A. Maile
Life of this patent
Estimating the term…
Abstract
The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
Claims12
A method of inhibiting cell division of an endothelial cell, comprising contacting the endothelial cell with an effective amount of an antibody that:
- (a) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a human β3 integrin, wherein said amino acids consist of SEQ ID NO:
- 82;
- (b) does not specifically bind to the RGD binding site of a human β3 integrin;
- and (c) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a pig β3 integrin, wherein said amino acids consist of SEQ ID NO:
- 82, thereby inhibiting cell division of the endothelial cell.
2 more elements
A method of inhibiting vitronectin occupancy of a human β3 integrin, comprising contacting an endothelial cell comprising a human β3 integrin in the presence of vitronectin with an effective amount of an antibody that:
- (a) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a human β3 integrin, wherein said amino acids consist of SEQ ID NO:
- 82;
- (b) does not specifically bind to the RGD binding site of a human β3 integrin;
- and (c) specifically binds to the cysteine loop domain at amino acids 177 to 184 of a pig β3 integrin, wherein said amino acids consist of SEQ ID NO:
- 82, thereby inhibiting vitronectin occupancy of the human β3 integrin.
2 more elements
Dependencies are inferred from the claim text.